Stay updated on Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Sign up to get notified when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.

Latest updates to the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page
- Check8 days agoChange DetectedThe page shows a new Revision: v3.5.5 label, replacing the previous Revision: v3.5.4. This indicates an update to the page's revision history rather than a change to study content.SummaryDifference0.0%

- Check15 days agoChange DetectedA new publication reference has been added to the Publications section, citing a 2026 Ther Adv Hematol article on ruxolitinib in GVHD. This addition expands the related literature linked to the REACH3 study page without modifying study details or eligibility.SummaryDifference0.0%

- Check22 days agoChange DetectedThe page's revision has been updated to v3.5.4, signaling a small maintenance or metadata update rather than a change to the study data.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page now shows a revised tag 'Revision: v3.5.3', indicating an updated version of the page content. The previous revision tag 'v3.5.2' was replaced.SummaryDifference0.0%

- Check51 days agoChange DetectedThe page now displays an updated site revision marker (v3.5.2 instead of v3.5.0). This reflects a technical site/version update without changing the study information shown.SummaryDifference0.0%

- Check80 days agoChange DetectedRevision history updated: added v3.5.0 and removed v3.4.3.SummaryDifference0.0%

Stay in the know with updates to Ruxolitinib vs BAT in Chronic GvHD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ruxolitinib vs BAT in Chronic GvHD Clinical Trial page.